BMI View: The Irish government's four-year agreement with the pharmaceutical industry with regard to
drug pricing reflects the government's continued focus on cost control measures targeting pharmaceutical
expenditure. The agreed price-reduction mechanism for existing ..."
BMI View: The export-oriented Irish pharmaceutical industry will continue to benefit from its R&D and
manufacturing capabilities as well as its competitive business environment. While the new US federal rules
on so-called corporate inversion deals will mitigate purely ..."
BMI View: Ireland's pharmaceutical and healthcare sector will continue to observe strong development
over a multi-quarter horizon. This outlook is reflected in ongoing solid levels of investment and job creation
in both the pharmaceutical and healthcare industries. Wh ..."
BMI View: In line with our long-standing view, manufacturing investment in Ireland's pharmaceutical
sector remained strong in H215, and we expect this trend to continue over a multi-quarter horizon.
Sustained expansion of Ireland's economy will be underpinned by an in ..."
BMI View: Continued manufacturing investment in Ireland's pharmaceutical sector will continue to be
promoted by government support and operational advantages such as high level of manufacturing and
compliance, skilled workforce and easy access to key export markets. W ..."
BMI View: In line with our long-standing view, merger and acquisition activity targeting Irish
pharmaceutical firms has remained intense in H115, while this trend is expected to continue over a multiquarter
horizon against a backdrop of strong fundamentals and Ireland ..."
BMI View: Merger and acquisition activity targeting Irish pharmaceutical companies will remain strong
due to long-term fundamentals, including promising drug pipelines, investment and innovation incentives
and higher productivity by existing levels of industry agglome ..."
BMI View: The US Treasury Department's modification of tax rules in order to discourage tax inversions
will continue to curb the number of M&A deals in the pharmaceutical industry that allow companies to be
headquartered in Ireland. This is reflected in the recent wit ..."
BMI View: The US government and the OECD recent proposals to discourage corporate inversion pose
downside risk to the rate of M&A deals that opt to establish their new headquarters' domicile in Ireland,
although the megatrend of consolidation within the pharmaceutical ..."
BMI View: We anticipate further cuts to healthcare spending to come in the coming months, in the wake of
an EU Commission report citing public healthcare expenditure in Ireland as one of the highest in Europe.
This will have a knock-on effect on government pharmaceuti ..."